Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads In Gynecologic Cancer

Gynecologic Cancer for May/June 2019

Chemoradiotherapy no better than chemo alone in endometrial carcinoma,

Cediranib may alter DNA repair capacity,

Targeted sequencing panel IDs Lynch syndrome in women with/at risk for endometrial cancer,

Anomalous RT dose linked to lower survival in uterine cancer,

Thrice yearly cytologic testing may best annual cervical screenings,

More must reads

Gynecologic Cancer for March/April 2019

Vaginal brachytherapy more toxic than pelvic RT in endometrial carcinoma,

In endometrial cancer and SUI, concomitant surgery improves outcomes,

Pembrolizumab benefits some patients with advanced cervical cancer,

Financial Assistance Programs May Aid in Treatment of Cervical Cancer,

Neratinib Shows Promise in HER2-mutant Cervical Cancer,

More must reads

Gynecologic Cancer for January/February 2019

Researchers characterize novel subtype of endocervical adenocarcinoma,

Mucinous ovarian tumor survival rates stress correct diagnosis,

More must reads

Gynecologic Cancer for September/October 2018

Uterine serous carcinoma patients have continuous high risk of VTE , Gressel GM et al. Obstet Gynecol. 2018 Oct 5;132:1130-6.
More must reads

Gynecologic Cancer for November/December 2017

CD8+ Tumor-Infiltrating Lymphocytes and Ovarian Ca, JAMA Oncol; ePub 2017 Oct 12; OTTA Consortium
More must reads

Pages